Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
- A presentation at the 2020
Wedbush PacGrow Healthcare Virtual Conferenceon Wednesday, August 12, 2020at 11:30 a.m. ET/ 8:30 a.m. PT; and
- A “Bispecifics Frontiers: Exploring new biologies and advancing novel therapeutics” panel at the Canaccord Genuity 40th Annual Growth Conference on
Thursday, August 13, 2020at 1 p.m. ET/ 10 a.m. PT.
A live audio webcast of the presentation and panel will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing of clinical trials. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the
Chief Financial Officer
Source: Harpoon Therapeutics